Anika Therapeutics (ANIK) Net Margin (2010 - 2025)

Anika Therapeutics (ANIK) has 16 years of Net Margin data on file, last reported at 4.93% in Q4 2025.

• On a quarterly basis, Net Margin rose 5840.0% year-over-year to 4.93% in Q4 2025; TTM through Mar 2026 was 0.01%, a 3924.0% increase from a year earlier, with the FY2025 full-year figure at 0.8%, up 3886.0% from the prior year.
• Net Margin for Q4 2025 stood at 4.93%, down from 3.04% in the prior quarter.
• Over the last five years, Net Margin for ANIK reached as high as 17.12% in Q2 2021 and fell as low as 534.43% in Q4 2023.
• Historically, Net Margin has averaged 60.53% across 5 years, with a median of 7.58% in 2022.
• Across the five-year window, Net Margin plunged 40621 bps in 2022 and jumped 47110 bps in 2024, its largest moves.
• Year by year, Net Margin stood at 29.92% in 2021, then sank by 1357 bps to 436.13% in 2022, then dropped by 23 bps to 534.43% in 2023, then surged by 88 bps to 63.33% in 2024, then surged by 92 bps to 4.93% in 2025.
• Per Business Quant data, the three most recent Net Margin figures were 4.93% in Q4 2025, 3.04% in Q3 2025, and 2.4% in Q2 2025.